Literature DB >> 23297722

Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement.

Bryan M Clary1, Axel Grothey, Scott Kopetz, Robert D W Marsh.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23297722      PMCID： PMC3719917          DOI： 10.1111/j.1477-2574.2012.00598.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN： 1365-182X            Impact factor:   3.647


× No keyword cloud information.
  9 in total

1.  Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis.

Authors:  Laura Rubbia-Brandt; Gregory Y Lauwers; Huamin Wang; Pietro E Majno; Kenneth Tanabe; Andrew X Zhu; Catherine Brezault; Olivier Soubrane; Eddie K Abdalla; Jean-Nicolas Vauthey; Gilles Mentha; Benoit Terris
Journal:  Histopathology       Date:  2010-03       Impact factor: 5.087

2.  A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.

Authors:  M Ychou; W Hohenberger; S Thezenas; M Navarro; J Maurel; C Bokemeyer; E Shacham-Shmueli; F Rivera; C Kwok-Keung Choi; A Santoro
Journal:  Ann Oncol       Date:  2009-06-30       Impact factor: 32.976

3.  Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials.

Authors:  Chengyao Zhang; Jiawu Wang; Haitao Gu; Daihua Zhu; Yang Li; Peng Zhu; Yaxu Wang; Jijian Wang
Journal:  Oncol Lett       Date:  2012-01-16       Impact factor: 2.967

4.  Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement.

Authors:  Roderich E Schwarz; Jordan D Berlin; Heinz J Lenz; Bernard Nordlinger; Laura Rubbia-Brandt; Michael A Choti
Journal:  HPB (Oxford)       Date:  2012-09-24       Impact factor: 3.647

5.  Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases.

Authors:  Yoji Kishi; Daria Zorzi; Carlo M Contreras; Dipen M Maru; Scott Kopetz; Dario Ribero; Manuela Motta; Nicoletta Ravarino; Mauro Risio; Steven A Curley; Eddie K Abdalla; Lorenzo Capussotti; Jean-Nicolas Vauthey
Journal:  Ann Surg Oncol       Date:  2010-06-22       Impact factor: 5.344

6.  Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.

Authors:  Leonard B Saltz; Donna Niedzwiecki; Donna Hollis; Richard M Goldberg; Alexander Hantel; James P Thomas; Anthony L A Fields; Robert J Mayer
Journal:  J Clin Oncol       Date:  2007-08-10       Impact factor: 44.544

7.  A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.

Authors:  J Randolph Hecht; Edith Mitchell; Tarek Chidiac; Carroll Scroggin; Christopher Hagenstad; David Spigel; John Marshall; Allen Cohn; David McCollum; Philip Stella; Robert Deeter; Seta Shahin; Rafael G Amado
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

8.  Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

Authors:  Jolien Tol; Miriam Koopman; Annemieke Cats; Cees J Rodenburg; Geert J M Creemers; Jolanda G Schrama; Frans L G Erdkamp; Allert H Vos; Cees J van Groeningen; Harm A M Sinnige; Dirk J Richel; Emile E Voest; Jeroen R Dijkstra; Marianne E Vink-Börger; Ninja F Antonini; Linda Mol; Johan H J M van Krieken; Otilia Dalesio; Cornelis J A Punt
Journal:  N Engl J Med       Date:  2009-02-05       Impact factor: 91.245

9.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.

Authors:  Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Michel Praet; Ullrich Bethe; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321
  9 in total
  2 in total

1.  Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer.

Authors:  Pradeep S Virdee; Joanna Moschandreas; Val Gebski; Sharon B Love; E Anne Francis; Harpreet S Wasan; Guy van Hazel; Peter Gibbs; Ricky A Sharma
Journal:  JMIR Res Protoc       Date:  2017-03-28

2.  Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study.

Authors:  Peter Gibbs; Val Gebski; Mark Van Buskirk; Kenneth Thurston; David N Cade; Guy A Van Hazel
Journal:  BMC Cancer       Date:  2014-12-01       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.